NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free ALNY Stock Alerts $147.41 -1.86 (-1.25%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$147.22▼$151.0050-Day Range$146.65▼$198.2052-Week Range$143.52▼$218.88Volume460,718 shsAverage Volume909,009 shsMarket Capitalization$18.57 billionP/E RatioN/ADividend YieldN/APrice Target$216.12 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alnylam Pharmaceuticals alerts: Email Address Alnylam Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.58 Rating ScoreUpside/Downside46.6% Upside$216.12 Price TargetShort InterestHealthy2.41% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment0.76Based on 10 Articles This WeekInsider TradingSelling Shares$5.85 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.61) to ($2.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.89 out of 5 starsMedical Sector33rd out of 947 stocksPharmaceutical Preparations Industry12th out of 435 stocks 4.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 11 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $216.12, Alnylam Pharmaceuticals has a forecasted upside of 46.6% from its current price of $147.41.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.41% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 23.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 3.2 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Alnylam Pharmaceuticals this week, compared to 9 articles on an average week.Search Interest14 people have searched for ALNY on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,850,000.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions93.98% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($4.61) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -41.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -41.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More ALNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALNY Stock News HeadlinesMarch 15, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by StockNews.comMarch 14, 2024 | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest UpdateMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 13, 2024 | businesswire.comAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYMarch 11, 2024 | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by BrokeragesMarch 11, 2024 | americanbankingnews.comZacks Research Weighs in on Alnylam Pharmaceuticals, Inc.'s FY2026 Earnings (NASDAQ:ALNY)March 10, 2024 | seekingalpha.comIs Alnylam's HELIOS-B Delay A Red Flag?March 18, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 6, 2024 | finance.yahoo.comAlnylam, Roche blood pressure drug scores in second mid-stage trialMarch 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and IO Biotech (IOBT)March 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alnylam Pharma as Zilebesiran Shows Blockbuster PotentialMarch 5, 2024 | msn.comAlnylam, Roche mark second Phase 2 win for blood pressure therapyMarch 5, 2024 | finance.yahoo.comRoche, Alnylam say blood pressure drug succeeds in mid-stage trialMarch 5, 2024 | businesswire.comAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNYMarch 1, 2024 | benzinga.comDecoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?February 29, 2024 | markets.businessinsider.comOptimistic Buy Rating for BridgeBio Pharma Amid Strong Market Position and Promising Treatment PipelineFebruary 27, 2024 | finance.yahoo.comAlnylam to Webcast Presentations at Upcoming March Investor ConferencesFebruary 27, 2024 | businesswire.comAlnylam to Webcast Presentations at Upcoming March Investor ConferencesFebruary 23, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Alnylam Pharma (ALNY) and Bausch Health Companies (BHC)February 21, 2024 | finance.yahoo.comAlnylam Pharmaceuticals, Inc.: Alnylam Earnings: Robust Uptake of Amvuttra Drives Sales; Shares UndervaluedFebruary 21, 2024 | msn.comMarket Shifts: Upgrades and Downgrades Sweep Across Tech, Finance, and Healthcare StocksFebruary 20, 2024 | finance.yahoo.comCodexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory BoardFebruary 17, 2024 | msn.comAlnylam Pharmaceuticals’ New Regulation Risk – A Cause for Worry?February 17, 2024 | finance.yahoo.comAlnylam Pharmaceuticals Full Year 2023 Earnings: In Line With ExpectationsFebruary 17, 2024 | finance.yahoo.comALNY Mar 2024 130.000 putSee More Headlines Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$216.12 High Stock Price Target$395.00 Low Stock Price Target$161.00 Potential Upside/Downside+46.6%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($3.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-24.08% Pretax Margin-23.71% Return on EquityN/A Return on Assets-12.18% Debt Debt-to-Equity RatioN/A Current Ratio3.08 Quick Ratio2.99 Sales & Book Value Annual Sales$1.83 billion Price / Sales10.16 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-83.76Miscellaneous Outstanding Shares125,950,000Free Float124,183,000Market Cap$18.57 billion OptionableOptionable Beta0.39 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Comp: $2.09MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Comp: $972.35kDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Comp: $1.24MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Comp: $1MMs. Indrani M. Lall Franchini J.D. (Age 51)Executive VP & Secretary Comp: $958.96kMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan LippmanChief Corporate Development & Strategy OfficerMore ExecutivesKey CompetitorsRoyalty PharmaNASDAQ:RPRXBioMarin PharmaceuticalNASDAQ:BMRNMyoKardiaNASDAQ:MYOKUnited TherapeuticsNASDAQ:UTHRHorizon Therapeutics PublicNASDAQ:HZNPView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 287,064 shares on 3/11/2024Ownership: 9.483%Goldman Sachs Group Inc.Sold 20,677 shares on 3/1/2024Ownership: 0.231%Teachers Retirement System of The State of KentuckySold 21,042 shares on 2/26/2024Ownership: 0.024%V Square Quantitative Management LLCBought 274 shares on 2/21/2024Ownership: 0.000%Eventide Asset Management LLCBought 87,000 shares on 2/20/2024Ownership: 0.069%View All Insider TransactionsView All Institutional Transactions Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Alnylam Pharmaceuticals was last updated on Monday, March 18, 2024 at 12:19 AM. Pros Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.: Alnylam Pharmaceuticals focuses on developing novel therapeutics based on ribonucleic acid interference, which can lead to groundbreaking treatments for various diseases. The company's pipeline of investigational RNAi therapeutics targets genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases, showing a diverse range of potential treatments. Recent positive developments in the company's research and clinical trials indicate promising future prospects for new drug approvals and market expansion. Alnylam Pharmaceuticals has shown strong institutional investor holdings, reflecting confidence in the company's growth potential and stability. Despite fluctuations, the current stock price of Alnylam Pharmaceuticals presents a potentially attractive entry point for investors looking to capitalize on future growth. Cons Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons: Biopharmaceutical investments can be highly volatile due to regulatory challenges, clinical trial outcomes, and competitive pressures, posing risks to investor returns. The biopharmaceutical industry is subject to rapid technological advancements and evolving market dynamics, which can impact the success of drug development and commercialization. Market competition in the RNA interference therapeutics space is intensifying, potentially affecting Alnylam Pharmaceuticals' market share and pricing power. Investing in biopharmaceutical companies like Alnylam Pharmaceuticals requires a high tolerance for risk and a long-term investment horizon due to the inherent uncertainties in drug development and regulatory processes. Fluctuations in healthcare policies, pricing regulations, and global economic conditions can influence the financial performance and market valuation of Alnylam Pharmaceuticals. ALNY Stock Analysis - Frequently Asked Questions Should I buy or sell Alnylam Pharmaceuticals stock right now? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks. What is Alnylam Pharmaceuticals' stock price target for 2024? 19 brokers have issued 1-year price targets for Alnylam Pharmaceuticals' shares. Their ALNY share price targets range from $161.00 to $395.00. On average, they anticipate the company's share price to reach $216.12 in the next twelve months. This suggests a possible upside of 46.6% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. How have ALNY shares performed in 2024? Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of the year. Since then, ALNY stock has decreased by 23.0% and is now trading at $147.41. View the best growth stocks for 2024 here. Are investors shorting Alnylam Pharmaceuticals? Alnylam Pharmaceuticals saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 3,040,000 shares, a drop of 23.8% from the February 14th total of 3,990,000 shares. Based on an average daily trading volume, of 847,000 shares, the days-to-cover ratio is presently 3.6 days. View Alnylam Pharmaceuticals' Short Interest. When is Alnylam Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALNY earnings forecast. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The biopharmaceutical company had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. Alnylam Pharmaceuticals's revenue was up 31.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.68) EPS. What ETFs hold Alnylam Pharmaceuticals' stock? ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), Principal Healthcare Innovators ETF (BTEC) and VictoryShares Nasdaq Next 50 ETF (QQQN). What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital World Investors (12.89%), Vanguard Group Inc. (9.52%), Vanguard Group Inc. (9.48%), Baillie Gifford & Co. (5.55%), Dodge & Cox (2.92%) and Capital International Investors (2.86%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALNY) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.